Fresh Frozen Facts Part 4: A Thoughtful Look at Plasma Transfusion by Dr. Caitlin Raymond
Caitlin Raymond, MD/PhD shared an insightful chain of posts on LinkedIn:
”Fresh Frozen Facts, Part IV: Beyond the Blood Bag
We’ve spent the last three posts unpacking the nuances of plasma as a transfusion product — thawed, typed, and delivered with varying degrees of clarity and clinical intent. But plasma’s story doesn’t stop there.
In Part IV, we explore what happens after donation — when plasma is fractionated, purified, and turned into targeted biologics that power modern hematology, neurology, rheumatology, immunology, and more.
From albumin for oncotic support to IVIG for immune modulation and Rh immune globulin for alloimmunization prevention, these plasma-derived therapies are more than just “blood products.” They’re precision tools — crafted for specific indications and held to pharmaceutical-grade standards.
We cover:
- Albumin: when it’s the right choice — and when it isn’t
- IVIG: how it works, when to use it, and key risks to know
- RhIg: an elegant triumph of targeted immunotherapy
- Hyperimmune globulins, antithrombin, C1 esterase inhibitor, and more
- The evolving landscape of patient-centered transfusion, including care for Jehovah’s Witnesses and the legacy of hemophilia and HIV
This final installment is about precision, stewardship, and respect — for the science and the people behind every plasma product.
And if you’ve missed the earlier parts of the series, now’s the time to catch up.
Because transfusion medicine doesn’t end with a blood bag — and sometimes the most powerful plasma products don’t look like blood at all.
Read the full post here.
Caitlin Raymond, MD/PhD, has launched an educational series on Fresh Frozen Plasma (FFP), now available on her journal blog.
Enjoy the final part and make sure you do not miss all the Fresh Frozen Facts!

Stay tuned for updates to the Fresh Frozen Facts series on Hemostasis Today.
-
Nov 15, 2025, 12:24Thomas Reiser: Can AI Keep Up with Thrombosis Specialists?
-
Nov 15, 2025, 12:13Michael Makris on Immediate Suspension of Use of Plasma Derived FIX Concentrates in Punjab
-
Nov 15, 2025, 09:32Tushar Pandey: Hounoured to Be Part of Hematocon 2025
-
Nov 15, 2025, 09:11Lisa Murphy invites You to Join Her at Stroke Foundation’s Run4Stroke Marathon
-
Nov 15, 2025, 08:56Ahmed Bennis on Potential Use of P2Y12 Inhibitors as Safer Alternative in Monotherapy
-
Nov 15, 2025, 08:39Marika Nöjd: Donating Blood is An Easy Way to Do Good!
-
Nov 15, 2025, 08:19Joseph Caprini Released His UIP 2025 Session on VTE Recurrence Risk
-
Nov 15, 2025, 07:14Paul Bolaji Invites You to ”Thrombolytic Therapy in Acute Stroke in African Patients” Seminar
-
Nov 15, 2025, 07:03Carla Goulart Peron Explores The Role of Technology and Collaboration in Global Stroke Action
